Lenacapavir: An Overview’

  • Unique Paper ID: 158616
  • Volume: 9
  • Issue: 10
  • PageNo: 251-265
  • Abstract:
  • Lenacapavir was approved for medical use in European Union in August-2022, Lenacapavir is the first of a new class of drugs called "Capsid inhibitors to be FDA-approved for treating HIV/AIDS. Lenacapavir a new type of antiretroviral medication for adult patients living with Human Immunodeficiency Virus type-1(HIV-1), who’s HIV Infections cannot be successfully treated with other available treatments due to resistance, intolerance considerations. Lenacapavir works by blocking the HIV-1 virus' protein shell (the Capsid) .Lenacapvir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type-1 (HIV-1)-Infection. Lenacapvir first formulation Oral Tablets and Subcutaneous injection-form at trade Name-(Sunlenac), Lenacapavir -is achieved in HIV RNA suppression .Lenacapvir is a long- acting, potent inhibitor of the HIV Capsid protein. Lenacapavir binds directly to HIV-capsid in a pocket between capsid protein subunits in hexamers.Treatement of emergent resistance to lenacapvir has been reported in the phase 2/3 CAPELLA trail evaluating Lenacapvir for HIV treatment. Combination antiretroviral therapy-suppression HIV-1 replication and increase CD 4+ cell counts.

Copyright & License

Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

BibTeX

@article{158616,
        author = {D.NAGAVALLI and P.NANTHAGOPAL},
        title = {Lenacapavir: An Overview’},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {9},
        number = {10},
        pages = {251-265},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=158616},
        abstract = {       Lenacapavir was approved for medical use in European Union in August-2022, Lenacapavir is the first of a new class of drugs called "Capsid inhibitors to be FDA-approved for treating HIV/AIDS. Lenacapavir a new type of antiretroviral medication for adult patients living with Human Immunodeficiency Virus type-1(HIV-1), who’s HIV Infections cannot be successfully treated with other available treatments due to resistance, intolerance considerations. Lenacapavir works by blocking the HIV-1 virus' protein shell (the Capsid) .Lenacapvir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type-1 (HIV-1)-Infection. Lenacapvir first formulation Oral Tablets and Subcutaneous injection-form at trade Name-(Sunlenac), Lenacapavir -is achieved in HIV RNA suppression .Lenacapvir is a long- acting, potent inhibitor of the HIV Capsid protein. Lenacapavir binds directly to HIV-capsid in a pocket between capsid protein subunits in hexamers.Treatement of emergent resistance to lenacapvir has been reported in the phase 2/3 CAPELLA trail evaluating Lenacapvir for HIV treatment. Combination antiretroviral therapy-suppression HIV-1 replication and increase CD 4+ cell counts. },
        keywords = {Lenacapavir, Capsid-Inhibitor, HIV-1, Anti-Retroviral agent, SUNLENCA.},
        month = {},
        }

Cite This Article

  • ISSN: 2349-6002
  • Volume: 9
  • Issue: 10
  • PageNo: 251-265

Lenacapavir: An Overview’

Related Articles